



# Asthma

## 2020 Adult Asthma Data: Prevalence Tables and Maps

Table L2.1  
 Adult<sup>a</sup> Lifetime<sup>b</sup> Asthma Prevalence  
 by Sex at Birth and State or Territory: BRFSS 2020

State	Male Sample Size <sup>c</sup>	Male Prevalence (Percent)	Male Standard Error	Male 95% CI <sup>d</sup> (Percent)	    	Female Sample Size <sup>c</sup>	Female Prevalence (Percent)	Female Standard Error (Percent)	Female 95% CI <sup>d</sup> (Percent)
U.S. Total <sup>f</sup>	180,274	11.5	0.17	(11.1–11.8)		213,200	16.1	0.19	(15.7–16.5)
AL	2,170	13.2	0.97	(11.3–15.1)		3,163	16.0	0.85	(14.3–17.7)
AK	1,810	10.5	1.30	(7.9–13.0)		1,845	17.8	1.44	(14.9–20.6)
AZ	4,748	12.1	0.66	(10.8–13.4)		5,505	16.8	0.74	(15.4–18.2)
AR	2,181	9.8	0.83	(8.2–11.5)		3,046	15.1	1.04	(13.0–17.1)
CA	2,330	13.0	0.94	(11.2–14.9)		2,451	17.2	1.08	(15.1–19.3)
CO	4,998	11.8	0.54	(10.7–12.9)		5,161	16.3	0.62	(15.1–17.5)
CT	4,075	13.1	0.86	(11.4–14.8)		4,871	17.1	0.84	(15.4–18.7)
DE	1,785	13.4	1.27	(11.0–15.9)		2,232	15.4	1.07	(13.3–17.5)
DC	1,547	14.5	1.22	(12.1–16.9)		1,872	17.2	1.26	(14.7–19.7)
FL	5,348	10.0	0.79	(8.4–11.5)		6,420	13.4	0.82	(11.8–15.0)
GA	3,964	11.7	0.91	(9.9–13.5)		5,090	14.7	0.81	(13.1–16.3)

State	Male Sample Size <sup>c</sup>	Male Prevalence (Percent)	Male Standard Error	Male 95% CI <sup>d</sup> (Percent)	    	Female Sample Size <sup>c</sup>	Female Prevalence (Percent)	Female Standard Error (Percent)	Female 95% CI <sup>d</sup> (Percent)
HI	3,560	12.3	0.78	(10.8–13.8)		4,185	16.6	0.78	(15.1–18.2)
ID	2,889	10.2	0.85	(8.5–11.8)		3,069	15.7	0.94	(13.9–17.6)
IL	1,705	10.0	0.90	(8.3–11.8)		1,972	14.3	1.06	(12.3–16.4)
IN	3,824	11.5	0.63	(10.2–12.7)		4,626	16.3	0.68	(15.0–17.7)
IA	4,608	9.4	0.53	(8.3–10.4)		5,007	14.4	0.61	(13.2–15.6)
KS	4,876	11.9	0.62	(10.6–13.1)		5,607	16.4	0.68	(15.1–17.8)
KY	1,839	13.4	1.02	(11.4–15.4)		2,081	18.7	1.12	(16.5–20.9)
LA	2,155	12.9	1.06	(10.9–15.0)		2,583	15.2	0.92	(13.4–17.0)
ME	4,498	13.0	0.81	(11.4–14.6)		6,463	16.5	0.77	(15.0–18.0)
MD	6,411	11.2	0.60	(10.0–12.4)		7,835	14.8	0.57	(13.7–16.0)
MA	3,263	12.2	0.76	(10.7–13.7)		3,882	18.6	0.88	(16.9–20.4)
MI	3,201	11.9	0.79	(10.4–13.5)		4,041	18.8	0.82	(17.2–20.4)
MN	7,613	9.5	0.42	(8.7–10.4)		8,182	14.4	0.48	(13.5–15.3)
MS	2,566	12.4	0.84	(10.8–14.1)		3,900	15.9	0.82	(14.3–17.5)
MO	4,074	10.6	0.66	(9.3–11.9)		5,097	16.1	0.72	(14.7–17.5)
MT	3,128	12.0	0.71	(10.6–13.3)		3,172	18.3	0.90	(16.6–20.1)
NE	6,790	8.7	0.50	(7.7–9.7)		7,977	12.8	0.60	(11.6–13.9)

State	Male Sample Size <sup>c</sup>	Male Prevalence (Percent)	Male Standard Error	Male 95% CI <sup>d</sup> (Percent)	    	Female Sample Size <sup>c</sup>	Female Prevalence (Percent)	Female Standard Error (Percent)	Female 95% CI <sup>d</sup> (Percent)
NV	1,207	11.4	1.20	(9.0–13.7)		1,267	15.3	1.36	(12.6–17.9)
NH	2,830	12.5	0.88	(10.8–14.3)		3,586	18.1	0.90	(16.3–19.9)
NJ	5,454	10.8	0.57	(9.6–11.9)		5,882	14.3	0.59	(13.1–15.4)
NM	3,024	12.1	0.94	(10.2–13.9)		3,968	16.2	1.00	(14.3–18.2)
NY	6,685	12.0	0.58	(10.9–13.1)		8,028	15.2	0.56	(14.1–16.3)
NC	2,632	10.1	0.70	(8.7–11.4)		3,191	14.4	0.78	(12.9–15.9)
ND	2,155	9.1	0.88	(7.4–10.8)		2,298	14.8	1.15	(12.5–17.1)
OH	6,684	11.5	0.59	(10.3–12.7)		7,937	17.2	0.64	(15.9–18.5)
OK	2,169	13.3	0.91	(11.5–15.1)		2,854	17.5	0.91	(15.7–19.3)
OR	2,595	12.5	0.76	(11.0–13.9)		2,809	18.7	0.87	(17.0–20.4)
PA	2,746	12.4	0.89	(10.7–14.2)		2,780	17.9	0.98	(16.0–19.8)
RI	2,297	12.4	1.05	(10.3–14.5)		3,067	19.0	1.08	(16.9–21.1)
SC	1,785	10.9	0.94	(9.0–12.7)		2,217	16.8	1.04	(14.8–18.9)
SD	3,068	8.6	1.03	(6.6–10.6)		3,841	13.5	1.26	(11.0–16.0)
TN	2,103	12.4	0.97	(10.5–14.3)		2,538	18.8	1.10	(16.6–20.9)
TX	5,187	8.9	0.72	(7.5–10.3)		5,807	15.5	0.95	(13.6–17.4)
UT	5,327	14.9	0.63	(13.6–16.1)		5,548	17.7	0.67	(16.4–19.0)

State	Male Sample Size <sup>c</sup>	Male Prevalence (Percent)	Male Standard Error	Male 95% CI <sup>d</sup> (Percent)	    	Female Sample Size <sup>c</sup>	Female Prevalence (Percent)	Female Standard Error (Percent)	Female 95% CI <sup>d</sup> (Percent)
VT	2,890	11.3	0.86	(9.6–12.9)		3,625	18.7	1.04	(16.7–20.8)
VA	4,261	10.5	0.65	(9.2–11.7)		5,249	16.5	0.73	(15.0–17.9)
WA	6,066	13.0	0.57	(11.9–14.2)		6,792	16.9	0.59	(15.8–18.1)
WV	2,572	15.3	0.95	(13.5–17.2)		3,292	18.5	0.86	(16.8–20.2)
WI	2,431	11.9	0.99	(10.0–13.9)		2,654	15.7	1.05	(13.6–17.7)
WY	2,150	12.5	1.03	(10.5–14.6)		2,635	17.6	1.21	(15.2–19.9)
<b>Territories</b>									
GU	1,015	7.2	1.30	(4.6–9.7)		1,166	13.5	1.97	(9.6–17.3)
PR	1,975	14.1	1.32	(11.5–16.7)		2,961	18.6	1.10	(16.4–20.8)

Notes: For additional information on methods and variable description, refer to 'Technical Information', available at:

<https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html>

<sup>a</sup>Aged 18+ years

<sup>b</sup>Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?

<sup>c</sup>Unweighted number of respondents who answered the lifetime asthma question

<sup>d</sup>CI denotes confidence interval

<sup>e</sup>Weighted number of the respondents who answered the lifetime asthma question

<sup>f</sup>U.S. Total includes 50 states plus the District of Columbia and excludes the territories

'-/blank': Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30%

**Asthma and Community Health Branch, National Center for Environmental Health  
Centers for Disease Control and Prevention**

Page last reviewed: March 1, 2022